How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?

Authors:
  • TATarso Adoni
    Tarso Adoni
  • AAAndrea Anacleto
    Andrea Anacleto
  • JBJoseph Bruno Bidin Brooks
    Joseph Bruno Bidin Brooks
  • MCMargarete de Jesus Carvalho
    Margarete de Jesus Carvalho
  • RCRinaldo Claudino
    Rinaldo Claudino
  • ADAlfredo Damasceno
    Alfredo Damasceno
  • MFMaria Lucia Brito Ferreira
    Maria Lucia Brito Ferreira
  • PGPaulo Diniz da Gama
    Paulo Diniz da Gama
  • MGMarcus Vinicus Magno Goncalves
    Marcus Vinicus Magno Goncalves
  • AGAnderson Kuntz Grzesiuk
    Anderson Kuntz Grzesiuk
  • AMAndre Palma da Cunha Matta
    Andre Palma da Cunha Matta

Abstract
Tuberculosis continues to be a serious health problem worldwide. The disease continues to be underdiagnosed and not properly treated. In conditions that affect the immune system, such as multiple sclerosis (MS), latent tuberculosis may thrive and reactivate during the use of immunomodulatory and immunosuppressive drugs. Among the best treatment options for patients with latent or active tuberculosis who have MS are IFN-β, glatiramer acetate and mitoxantrone. Drugs leading to a reduced number and/or function of lymphocytes should be avoided or used with caution. Tuberculosis must always be investigated in patients with MS and treated with rigor.

This publication has 86 references indexed in Scilit: